Phase II study of TS-1 chemotherapy as adjuvant treatment after resection of hepatic metastases from colorectal cancer

Phase II study of TS-1 chemotherapy as adjuvant treatment after resection of hepatic metastases from colorectal cancer - Phase II study of TS-1 as adjuvant treatment after resection of hepatic metastases from colorectal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001498

Enrollment

Registered

2008-11-12

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver metastases of colorectal cancer

Interventions

TS-1 chemotherapy as adjuvant treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Histologically confirmed metastatic liver tumors of colorectal adenocarcinoma (2) RO resection of both primary and metastatic tumor (3) No extrahepatic metastases (4) No prior chemotherapy (except for adjuvant chemotherapy for primary tumor) (5)PS (ECOG): 0-1 (6)Adequate major organ function (7)Written informed consent

Exclusion criteria

Exclusion criteria: (1) Prior chemotherapy with TS-1 (2) Multiple cancer (3) Severe complication (4) Active diarrhea (5) Prebious history of severe drug-induced allergy (6) Pregnant (7) Disqualified by attending doctor

Design outcomes

Primary

Measure	Time frame
disease free survival	—

Secondary

Measure	Time frame
overall survival, side effect	—

Countries

Japan

Contacts

Public ContactKeisuke Uehara

Nagoya University Graduate School of Medicine Division of Surgical Oncology

kuehara@med.nagoya-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026